Immune Adverse Events With Adjuvant Ipilimumab in Melanoma: Use of Immunosuppressants and Association With Outcome
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Immune Adverse Events (irAEs) With Adjuvant Ipilimumab in Melanoma, Use of Immunosuppressants and Association With Outcome: ECOG-ACRIN E1609 Study Analysis
J Immunother Cancer 2021 May 01;9(5)e002535, AA Tarhini, N Kang, SJ Lee, FS Hodi, GI Cohen, O Hamid, LF Hutchins, JA Sosman, HM Kluger, Z Eroglu, HB Koon, DP Lawrence, KL Kendra, DR Minor, CB Lee, MR Albertini, LE Flaherty, TM Petrella, H Streicher, VK Sondak, JM KirkwoodFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.